The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

Advances in Cancer Treatment and Quality of Life


EMBARGOED FOR RELEASE UNTIL EARLIER OF:
START OF PRESS BRIEFING OR START OF SCIENTIFIC SESSION

See attached summaries for exact times

CONTACT:
Annual Meeting News Room
312-949-3200

ASCO Media Information Line
212-584-5010

-- PRESS BRIEFING SATURDAY, MAY 31, 11:00 AM CDT --

-- Vaginal Brachytherapy Just as Effective as External Beam Radiation, Creates Fewer Side Effects in Patients with Endometrial Cancer; Gemcitabine Improves Survival in Patients with Early-Stage Pancreatic Cancer; Everolimus Delays Progression in Patients with Metastatic Kidney Cancer --

Chicago, IL—New studies evaluating the latest treatments and quality-of-life improvements for cancer patients were presented today at a press briefing of the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO).

“These studies identify promising new treatments for patients with some of the most hard-to-treat cancers, and new ways to improve patient symptoms and side effects to treatments,” said Nicholas Petrelli, MD, medical director of the Helen F. Graham Cancer Center in Wilmington, Delaware, and moderator of the press briefing. “And while much progress has been made in cancer research, both the disease and its treatment can take a toll on patients, so it’s critical that we keep looking for new ways to ease discomfort and improve quality of life.”

Late-breaking study findings include:

  • Vaginal brachytherapy is as effective as external beam radiation therapy at preventing the recurrence of endometrial cancer, and causes fewer side effects.

  • Gemcitabine (Gemzar) significantly increases survival for patients who have undergone surgery for early-stage pancreatic cancer – the first time chemotherapy has been shown to benefit these patients. Historically, there have been very few effective treatments for pancreatic cancer.

  • The experimental targeted therapy everolimus (RAD001, Cetican) improves progression free survival for patients whose advanced kidney cancer has progressed after other treatments – a finding which could lead to increased use of the drug earlier in the course treatment.

The press briefing also highlighted other research:

  •  A study evaluating the effectiveness of acupuncture for relieving pain and xerostomia (the inability to produce sufficient saliva, which can severely diminish a person’s quality of life) among patients with head and neck cancer. VIEW SUMMARY

  • A study that examines whether a eugeroic agent (a class of stimulants used to improved wakefulness) can help patients overcome severe cancer-related fatigue, one of the most common side effects of cancer treatment. VIEW SUMMARY

For consumer-oriented information on these studies and more than 120 cancer types and cancer-related syndromes, please refer your readers to ASCO’s oncologist-vetted patient website, www.cancer.net.

VIEW FULL PRESS RELEASE





 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005–2012 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.
Feedback Form